Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study.
Background Inflammation is a shared pathogenic pathway underlying multiple chronic conditions and contributes to a loss of healthspan. This study aimed to evaluate the effect of low-dose aspirin on the loss of healthspan in older individuals. Methods ASPirin in Reducing Events in the Elderly (ASPREE...
| Publicado en: | Age & Ageing Vol. 55; no. 7; pp. 1 - 11 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Artículo |
| Publicado: |
Oxford University Press / USA
Jul2026
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=195867373&site=ehost-live header: @attributes: shortDbName: ssf uiTerm: 195867373 longDbName: Social Sciences Full Text (H.W. Wilson) uiTag: AN controlInfo: bkinfo: jinfo: jid: 00020729 AGA jtl: Age & Ageing issn: 00020729 maglogo: N pubinfo: dt: Jul2026 vid: 55 iid: 7 pid: 622 pub: Oxford University Press / USA artinfo: ui: 195867373 10.1093/ageing/afag218 ppf: 1 ppct: 10 formats: tig: atl: Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study. aug: au: Zheng, Haoxin Tina Phyo, Aung Zaw Zaw Wu, Zimu Orchard, Suzanne G Owen, Alice Espinoza, Sara E Sheets, Kerry Woods, Robyn Ryan, Joanne affil: School of Public Health and Preventive Medicine, Monash University School of Public Health and Preventive Medicine, 503 St Kilda Rd. Melbourne VIC 3004 Australia Division of Geriatrics, Gerontology and Palliative Medicine, UT Health San Antonio, San Antonio, Texas, USA Division of Geriatric and Palliative Medicine, Department of Medicine, Hennepin Healthcare, Minneapolis, Minnesota, USABerman Center for Outcomes and Clinical Research, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA su: Australia United States Placebos Patient safety Blind experiment Sex distribution Smoking Hypertension Life expectancy Randomized controlled trials Age distribution Aging Drug efficacy Alcohol drinking Minorities Longevity Diabetes Old age Risk assessment Independent living Body mass index Hyperlipidemia Research funding Aspirin Statistical sampling Frail elderly Descriptive statistics Odds ratio Research methodology Comparative studies Data analysis software Confidence intervals Proportional hazards models Evaluation sug: subj: Placebos Patient safety Blind experiment Sex distribution Smoking Hypertension Life expectancy Randomized controlled trials Age distribution Aging Drug efficacy Alcohol drinking Minorities Longevity Diabetes Old age Australia United States Pharmaceutical and medicine manufacturing Medicinal and Botanical Manufacturing Drinking Places (Alcoholic Beverages) Marketing Research and Public Opinion Polling Risk assessment Independent living Body mass index Hyperlipidemia Research funding Aspirin Statistical sampling Frail elderly Descriptive statistics Odds ratio Research methodology Comparative studies Data analysis software Confidence intervals Proportional hazards models Evaluation keyword: aged aspirin aspirin low dose cancer cardiovascular diseases community copyrightHolder:British Geriatrics Society copyrightYear:2026 dementia diabetes mellitus healthspan https://dx.doi.org/10.1093/ageing/afag218 hypertension inLanguage:en older people publisher:Oxford University Press randomized controlled trial sameAs:https://pubmed.ncbi.nlm.nih.gov/42497096/ type 2 aged aspirin aspirin low dose cancer cardiovascular diseases community copyrightHolder:British Geriatrics Society copyrightYear:2026 dementia diabetes mellitus healthspan https://dx.doi.org/10.1093/ageing/afag218 hypertension inLanguage:en older people publisher:Oxford University Press randomized controlled trial sameAs:https://pubmed.ncbi.nlm.nih.gov/42497096/ type 2 ab: Background Inflammation is a shared pathogenic pathway underlying multiple chronic conditions and contributes to a loss of healthspan. This study aimed to evaluate the effect of low-dose aspirin on the loss of healthspan in older individuals. Methods ASPirin in Reducing Events in the Elderly (ASPREE) was a double-blind, placebo-controlled, randomised trial assessing the effect of daily low-dose aspirin for primary prevention. Community-dwelling participants aged ≥70 years [or ≥ 65 years for United States (US) minority ethnic groups] were recruited from Australia and the US. Eligible participants were initially free of major diseases with a life expectancy of more than five years and were randomly assigned to receive 100 mg of aspirin daily or a placebo. Loss of healthspan was defined as the first occurrence of cardiovascular disease, diabetes, dementia, cancer, or death. Results A total of 19 114 participants were followed for a median of 4.7 years, 5835 participants (30.5%) experienced a loss of healthspan. Participants who were older, male, smokers, or had hypertension, or frailty were more likely to experience healthspan loss during the trial. The rate of healthspan loss was 82.1 and 82.7 events per 1000 person-years in the aspirin and placebo groups, respectively. There was no evidence of a substantial difference in the risk of healthspan loss between the aspirin and placebo groups (hazard ratio, 0.98; 95% CI: 0.92–1.05). Conclusion Low-dose aspirin had no effect on the rate of loss of healthspan among older community-dwelling adults. Future studies should explore lifestyle and behavioural interventions to extend healthspan. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: N holdings: @attributes: islocal: N |
|---|